首页> 美国卫生研究院文献>Journal of Nuclear Medicine >Nanoparticles for Cardiovascular Imaging and Therapeutic Delivery Part 1: Compositions and Features
【2h】

Nanoparticles for Cardiovascular Imaging and Therapeutic Delivery Part 1: Compositions and Features

机译:用于心血管成像和治疗性递送的纳米粒子第1部分:成分和特征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Imaging agents made from nanoparticles are functionally versatile and have unique properties that may translate to clinical utility in several key cardiovascular imaging niches. Nanoparticles exhibit size-based circulation, biodistribution, and elimination properties different from those of small molecules and microparticles. In addition, nanoparticles provide versatile platforms that can be engineered to create both multimodal and multifunctional imaging agents with tunable properties. With these features, nanoparticulate imaging agents can facilitate fusion of high-sensitivity and high-resolution imaging modalities and selectively bind tissues for targeted molecular imaging and therapeutic delivery. Despite their intriguing attributes, nanoparticulate imaging agents have thus far achieved only limited clinical use. The reasons for this restricted advancement include an evolving scope of applications, the simplicity and effectiveness of existing small-molecule agents, pharmacokinetic limitations, safety concerns, and a complex regulatory environment. This review describes general features of nanoparticulate imaging agents and therapeutics and discusses challenges associated with clinical translation. A second, related review to appear in a subsequent issue of JNM highlights nuclear-based nanoparticulate probes in preclinical cardiovascular imaging.
机译:由纳米颗粒制成的显像剂在功能上具有多种用途,并具有独特的特性,可在几个关键的心血管显像领域转化为临床应用。纳米颗粒表现出与小分子和微粒不同的基于尺寸的循环,生物分布和消除特性。另外,纳米颗粒提供了通用平台,可以对其进行工程设计以创建具有可调特性的多峰和多功能成像剂。具有这些特征,纳米颗粒成像剂可以促进高灵敏度和高分辨率成像方式的融合,并选择性地结合组织以用于靶向分子成像和治疗性递送。尽管它们具有吸引人的属性,但是迄今为止,纳米颗粒成像剂仅获得了有限的临床用途。限制发展的原因包括不断发展的应用范围,现有小分子药物的简便性和有效性,药代动力学局限性,安全性问题以及复杂的监管环境。这篇综述描述了纳米颗粒成像剂和治疗剂的一般特征,并讨论了与临床翻译相关的挑战。在下一期JNM中出现的第二篇相关评论着重介绍了临床前心血管成像中基于核的纳米颗粒探针。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号